Ultragenyx Pharmaceutical (RARE) Competitors

Intra-Cellular Therapies (NASDAQ:ITCI) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Which has stronger earnings and valuation, ITCI or RARE?

Intra-Cellular Therapies has higher revenue and earnings than Ultragenyx Pharmaceutical. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intra-Cellular Therapies	$680.50M	20.59	-$139.67M	-$0.73	-180.48
Ultragenyx Pharmaceutical	$560.23M	6.42	-$569.18M	-$6.34	-6.13

Does the MarketBeat Community favor ITCI or RARE?

Ultragenyx Pharmaceutical received 316 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 77.52% of users gave Ultragenyx Pharmaceutical an outperform vote while only 66.50% of users gave Intra-Cellular Therapies an outperform vote.

Company	Underperform	Outperform
Intra-Cellular Therapies	Outperform Votes 522 66.50%	Underperform Votes 263 33.50%
Ultragenyx Pharmaceutical	Outperform Votes 838 77.52%	Underperform Votes 243 22.48%

Do analysts rate ITCI or RARE?

Intra-Cellular Therapies currently has a consensus price target of $106.08, suggesting a potential downside of 19.49%. Ultragenyx Pharmaceutical has a consensus price target of $92.79, suggesting a potential upside of 138.59%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Intra-Cellular Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intra-Cellular Therapies	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.47
Ultragenyx Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Do institutionals & insiders have more ownership in ITCI or RARE?

92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media prefer ITCI or RARE?

In the previous week, Ultragenyx Pharmaceutical had 4 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 8 mentions for Intra-Cellular Therapies. Ultragenyx Pharmaceutical's average media sentiment score of 1.40 beat Intra-Cellular Therapies' score of 1.31 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intra-Cellular Therapies	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Is ITCI or RARE more profitable?

Intra-Cellular Therapies has a net margin of -14.07% compared to Ultragenyx Pharmaceutical's net margin of -101.60%. Intra-Cellular Therapies' return on equity of -9.93% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intra-Cellular Therapies	-14.07%	-9.93%	-8.38%
Ultragenyx Pharmaceutical	-101.60%	-193.80%	-38.15%

Which has more volatility & risk, ITCI or RARE?

Intra-Cellular Therapies has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Summary

Ultragenyx Pharmaceutical beats Intra-Cellular Therapies on 10 of the 19 factors compared between the two stocks.